Managing Nausea and Vomiting in Cancer Patients
Author Information
Author(s): Warr D.G.
Primary Institution: Princess Margaret Hospital
Hypothesis
Can antiemetic therapies effectively reduce nausea and vomiting in cancer patients undergoing treatment?
Conclusion
Aprepitant significantly reduces vomiting in patients receiving chemotherapy, but many still experience nausea despite treatment.
Supporting Evidence
- Approximately 50% of cancer patients experience nausea or vomiting during treatment.
- Aprepitant improved control of vomiting by 15%-20% in patients receiving high-risk chemotherapy.
- Only a few controlled trials exist on the efficacy of antiemetics for cancer-related nausea.
Takeaway
Many cancer patients feel sick and throw up because of their treatment. Some medicines can help, but not everyone feels better.
Methodology
The study involved a prospective analysis of patients experiencing nausea and vomiting, assessing causes and treatment responses.
Potential Biases
The patients were already on antiemetics before admission, which may have influenced the results.
Limitations
The study had a high dropout rate and lacked a gold standard for diagnosing causes of emesis.
Participant Demographics
121 patients admitted to a hospice, with various causes of nausea and vomiting identified.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website